This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, R. N. Articles by Varnam, D. J. Search for Related Content PubMed PubMed Citation Articles by Jones, R. N. Articles by Varnam, D. J.

Impact of Modified Nonmeningeal Streptococcus pneumoniae Interpretive Criteria (NCCLS M100-S12) on the Susceptibility Patterns of Five Parenteral Cephalosporins: Report from the SENTRY Antimicrobial Surveillance Program (1997 to 2001)

The JONES Group/JMI Laboratories, North Liberty, Iowa 52317

Received 17 May 2002/ Accepted 19 August 2002

The revised interpretive criteria for Streptococcus pneumoniae recently published in the NCCLS M100-S12 informational supplement provide two sets of breakpoints for some cephalosporins: one set for meningeal infection isolates and a new set for nonmeningeal infection isolates. The net effect of these changes was to increase the reported rates of susceptibility of S. pneumoniae to the more active parenteral cephalosporins, such as cefepime, cefotaxime, and ceftriaxone, by 9.1 to 13.0%, bringing their in vitro rates much closer to those of amoxicillin (modified in an earlier NCCLS publication). These revised breakpoints will assist the rational prescribing of antimicrobial agents for the treatment of pneumococcal infections for specific types of infection and establish a greater correlation with clinical outcomes.

This article has been cited by other articles:

• Dagan, R., Garau, J. (2004). Appropriate Use of Antibiotics: Focus on Acute Otitis Media. CLIN PEDIATR 43: 313-321  
• Karlowsky, J. A., Jones, M. E., Draghi, D. C., Sahm, D. F. (2003). Clinical Isolates of Streptococcus pneumoniae with Different Susceptibilities to Ceftriaxone and Cefotaxime. Antimicrob. Agents Chemother. 47: 3155-3160 [Abstract] [Full Text]